Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has led to significant morbidity and mortality. While most suffer from mild symptoms, some patients progress to severe disease with acute respiratory distress syndrome (ARDS) and associated systemic hyperinflammation.
METHODS: First, to characterize key cytokines and their dynamics in this hyperinflammatory condition, we assessed abundance and correlative expression of a panel of 48 cytokines in patients progressing to ARDS as compared to patients with mild disease. Then, in an ongoing randomized controlled trial of convalescent plasma therapy (CPT), we analyzed rapid effects of CPT on the systemic cytokine dynamics as a correlate for the level of hypoxia experienced by the patients.
RESULTS: We identified an anti-inflammatory role of CPT independent of its neutralizing antibody content.
CONCLUSIONS: Neutralizing antibodies, as well as reductions in circulating interleukin-6 and interferon-γ-inducible protein 10, contributed to marked rapid reductions in hypoxia in response to CPT.
CLINICAL TRIAL REGISTRY OF INDIA: CTRI/2020/05/025209. http://www.ctri.nic.in/.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 224(2021), 4 vom: 16. Aug., Seite 565-574 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bandopadhyay, Purbita [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.08.2021 Date Revised 29.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiab010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329419080 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329419080 | ||
| 003 | DE-627 | ||
| 005 | 20240229233859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiab010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM329419080 | ||
| 035 | |a (NLM)34398242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bandopadhyay, Purbita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2021 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has led to significant morbidity and mortality. While most suffer from mild symptoms, some patients progress to severe disease with acute respiratory distress syndrome (ARDS) and associated systemic hyperinflammation | ||
| 520 | |a METHODS: First, to characterize key cytokines and their dynamics in this hyperinflammatory condition, we assessed abundance and correlative expression of a panel of 48 cytokines in patients progressing to ARDS as compared to patients with mild disease. Then, in an ongoing randomized controlled trial of convalescent plasma therapy (CPT), we analyzed rapid effects of CPT on the systemic cytokine dynamics as a correlate for the level of hypoxia experienced by the patients | ||
| 520 | |a RESULTS: We identified an anti-inflammatory role of CPT independent of its neutralizing antibody content | ||
| 520 | |a CONCLUSIONS: Neutralizing antibodies, as well as reductions in circulating interleukin-6 and interferon-γ-inducible protein 10, contributed to marked rapid reductions in hypoxia in response to CPT | ||
| 520 | |a CLINICAL TRIAL REGISTRY OF INDIA: CTRI/2020/05/025209. http://www.ctri.nic.in/ | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a cytokine | |
| 650 | 4 | |a hyperinflammation | |
| 650 | 4 | |a hypoxia | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a D'Rozario, Ranit |e verfasserin |4 aut | |
| 700 | 1 | |a Lahiri, Abhishake |e verfasserin |4 aut | |
| 700 | 1 | |a Sarif, Jafar |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Yogiraj |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Shekhar Ranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Rammohan |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Rajshekhar |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhuri, Kausik |e verfasserin |4 aut | |
| 700 | 1 | |a Bagchi, Saugata |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Ayan |e verfasserin |4 aut | |
| 700 | 1 | |a Perwez, Mohammed Masoom |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Biswanath Sharma |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Devlina |e verfasserin |4 aut | |
| 700 | 1 | |a Chakraborty, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Vasudevan, Janani Srinivasa |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Durba |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Chikam |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Bibhuti |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Prasun |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Shilpak |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Sandip |e verfasserin |4 aut | |
| 700 | 1 | |a Ganguly, Dipyaman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 224(2021), 4 vom: 16. Aug., Seite 565-574 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2021 |g number:4 |g day:16 |g month:08 |g pages:565-574 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiab010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2021 |e 4 |b 16 |c 08 |h 565-574 | ||